Illumina: Upgrade After a Clean Breakout — Buy the Momentum, Respect the Pullbacks
Illumina is trading up after the market reacted to recent regulatory and industry cues around sequencing-driven oncology diagnostics. Fundamentals remain solid (market cap ~$36.4B, FCF $931M, ROE ~29%), technicals show bullish momentum, and near-term catalysts could re-rate the stock. I recommend a swing trade entry with disciplined risk controls.